Kennedys advises Ascendis Pharma A/S (“Ascendis Pharma”) on exclusive distribution agreement

We advised Ascendis Pharma on an exclusive distribution agreement with Pendopharm, a division of Pharmascience Inc. for establishing a distributorship in Canada in respect of supplying a medicinal product, YORVIPATH® (developed as TransCon™ PTH) treating hypoparathyroidism.

Ascendis Pharma is a NASDAQ listed global pharmaceutical company headquartered in Copenhagen, Denmark with a particular focus on developing and commercialising medicinal products treating rare diseases.

The agreement is significant as YORVIPATH®, which is designated as an orphan drug in the European Union, will be the first approved treatment option available to patients in Canada living with chronic hypoparathyroidism.

We expect that this agreement will facilitate the supply and distribution process of YORVIPATH® in Canada, addressing unmet medical needs through providing life-saving treatment for patients with a rare condition, while also expanding Ascendis Pharma’s market presence.

This transaction was led by corporate and commercial partner Matthew Poli in collaboration with Myunghoon Paik (Hoon), an associate in our Products Law and Life Science team.

Matthew and Hoon commented: “We were thrilled to have advised Ascendis Pharma, bringing our specialised expertise in both life science and commercial practices in the complex regulatory frameworks associated with commercial agreements for medicinal products in the pharmaceutical industry.

"This successful transaction can provide substantial benefits to the client, ranging from financial gains and market expansion to enhanced reputation and strategic partnership, and also make a meaningful difference to so many patients’ lives.”